Literature DB >> 6605989

A DC-specific cytolytic T lymphocyte line is OKT8+1.

A M Krensky, C Clayberger, J L Greenstein, M Crimmins, S J Burakoff.   

Abstract

A human cytotoxic T lymphocyte (CTL) line, A9, was generated by limiting dilution and was selected because of its apparent DC specificity. A9 is 100% OKT3+, 90% OKT4+, and 10% OKT8+, but by negative selection the CTL present are entirely OKT8+. These OKT8+ CTL are totally inhibitable by Genox 3.53, an anti-DC1 monoclonal antibody (mAb), and Leu-10, an anti-DC subgroup mAb, but are not inhibitable by a panel of anti-HLA-DR mAb. These CTL are also inhibitable by anti-OKT3 and anti-LFA-2 but not by OKT4 or OKT8 mAb. These findings extend previous studies that showed that OKT8+ CTL recognize HLA-A,B antigens, whereas OKT4+ CTL recognize HLA-DR and SB antigens. It is possible that an as yet undefined T cell surface molecule is involved in DC recognition.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605989

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Recognition of class II molecules by human T cells. I. Analysis of epitopes of DR and DQ molecules in a DRw11, DRw52, DQw3 haplotype.

Authors:  L K Myers; E J Ball; G Nuñez; P Stastny
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis.

Authors:  R M Hoffmann; G R Pape; U Spengler; E P Rieber; J Eisenburg; J Döhrmann; G Paumgartner; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

3.  Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain.

Authors:  A Wright; J E Lee; M P Link; S D Smith; W Carroll; R Levy; C Clayberger; A M Krensky
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

4.  Alloreactive cytolytic T cell clones with dual recognition of HLA-B27 and HLA-DR2 antigens. Selective involvement of CD8 in their class I--directed cytotoxicity.

Authors:  P Aparicio; D Jaraquemada; J A López de Castro
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.